FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer

Sébastien Thureau (1) , Bernard Dubray (1, 2) , Romain Modzelewski (2, 3) , Pierre Bohn (2, 3) , Sébastien Hapdey (3, 2) , Sabine Vincent (1) , Elodie Anger , David Gensanne (1) , Nicolas Pirault (1) , Gouel Pierrick (3) , Pierre Vera (2, 3)

1 Département de radiothérapie et de physique médicale
2 QuantIF-LITIS - Equipe Quantification en Imagerie Fonctionnelle
3 Service de médecine nucléaire [Rouen]

Concomitant chemo-radiotherapy is the reference treatment for non-resectable locally-advanced Non-Small Cell Lung Cancer (NSCLC). Increasing radiotherapy total dose in the whole tumour volume has been shown to be deleterious. Functional imaging with positron emission tomography (PET/CT) offers the potential to identify smaller and biologically meaningful target volumes that could be irradiated with larger doses without compromising Organs At Risk (OAR) tolerance. This study investigated four scenarios, based on 18FDG and 18F-miso PET/CT, to delineate the target volumes and derive radiotherapy plans delivering up to 74Gy.

(RTEP5, NCT01576796 , registered 15 june 2012).

Mots clés: Positron emission tomography; Hypoxia; Lung cancer; Radiotherapy; 18fluoro-deoxy-D-glucose; 18fluoro-misonidasole

Domaines: Sciences du Vivant [q-bio]; Cancer

Sébastien Thureau, Bernard Dubray, Romain Modzelewski, Pierre Bohn, Sébastien Hapdey, et al.. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer. Radiation Oncology, 2018, 13 (1), pp.208. ⟨10.1186/s13014-018-1147-2⟩. ⟨hal-02102378⟩